68Ga-labeled inhibitor BiFAPI radionuclide labeled ligand of targeted fibroblast activating protein as well as preparation method and application of 68Ga-labeled inhibitor BiFAPI radionuclide labeled ligand

By developing a radionuclide-labeled ligand BiFAPI targeting fibroblast-activated protein binding to 68Ga, the [68Ga]Ga-BiFAPI radio probe was prepared, which solved the problem of insufficient tumor uptake specificity and retention time of existing FAP inhibitors in tumor uptake , achieving efficient diagnosis and evaluation of highly expressed FAP tumors.

CN118909037APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410894219.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing FAP inhibitors have shortcomings in tumor uptake specificity and retention time, especially the differences in uptake and retention time of small molecule drugs in different types of tumors, which is difficult to meet clinical needs.

Method used

A radionuclide-labeled ligand BiFAPI targeting fibroblast-activated protein was developed, and a [68Ga]Ga-BiFAPI radioactive probe was prepared using sodium acetate and [68Ga]GaCl3 by binding the compound BiFAPI to 68Ga. The reaction method was labeled and tested in combination with high performance liquid chromatography for tumor imaging and diagnosis.

Benefits of technology

[68Ga]Ga-BiFAPI shows the biological characteristics of highly specific targeted FAP, which is suitable for early diagnosis, pathological research and efficacy evaluation of highly expressed FAP tumors, and has a long tumor retention time and efficient tumor uptake ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909037A_ABST
    Figure CN118909037A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug synthesis, and particularly relates to a 68Ga-labeled targeted fibroblast activating protein inhibitor BiFAPI radionuclide labeled ligand as well as a preparation method and application thereof.The radioactive probe [68Ga] Ga-BiFAPI provided by the invention has the biological characteristic of specifically targeting FAP, can be used for early diagnosis and pathological research of FAP high-expression tumors, and has a good application prospect. Disease course development and curative effect evaluation are evaluated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug synthesis, and specifically relates to a novel radionuclide labeled ligand and a preparation method thereof, and more particularly to a method for 68 A Ga-labeled inhibitor BiFAPI radionuclide-labeled ligand targeting fibroblast activation protein, and a preparation method and application thereof. Background Art

[0002] Malignant tumors are one of the diseases that seriously threaten human health and are the second leading cause of death in the world. According to the latest global malignant tumor research report released by the World Health Organization's International Agency for Research on Cancer (IARC), China ranks first in the world in both the number of new cases and the number of deaths. China has become a "cancer superpower". In recent years, with the improvement of medical standards, the survival rate of cancer patients has increased significantly, but the level of early screening diagnosis and treatment of advanced metastatic tumors still needs to be improved. Therefore, many domestic and foreign scholars believe that new tumor diagnosis and treatment methods represented by radioactive targeted diagnosis and treatment integrated drugs (Theranostic) are of great value to tumor prevention and treatment.

[0003] The growth and spread of tumors depend not only on cancer cells but also on the non-malignant components of malignant lesions, which are classified as the matrix, which is composed of tumor-associated fibroblasts (CAFs) and extracellular matrix (ECM). Fibroblast activation protein (FAP) is a surface antigen specifically expressed by tumor-associated fibroblasts (CAFs) and is closely related to tumor growth, invasion, metastasis, immunosuppression and prognosis. FAP is a type II transmembrane serine protease that is low or basically not expressed in normal tissues and highly expressed in many epithelial malignancies, such as colorectal cancer, pancreatic cancer, ovarian cancer, hepatocellular carcinoma and non-small cell lung cancer. This characteristic makes it an important target for tumor targeted diagnosis and treatment, which is conducive to the non-invasive early diagnosis, staging, differential diagnosis and prognostic evaluation of FAP-highly expressed tumors.

[0004] There are many types of FAPI (FAP inhibitors), such as antibodies, peptides, and small molecules. Small molecule drugs have low molecular weight, higher tissue permeability, and faster clearance. The University of Antwerp has developed a highly efficient UAMC-1110 quinoline small molecule FAP inhibitor. Haberkorn et al. have chemically modified this framework and developed a series of quinoline-based derivatives including radioactive iodine-labeled FAPI-01 and radioactive metal-chelated FAPI-02. Due to the time-dependent increase in efflux and enzymatic deiodination of FAPI-01, it is not included in preclinical studies. Tumors have a high specific uptake of FAPI-02, but the tumor clearance is too fast after a long time and is not suitable for treatment. In order to overcome this shortcoming, the same group incorporated 4,4-difluoroalanine groups and finally screened out FAPI-04, which has an effective tumor uptake of 100% higher than FAPI-02 in 24 hours, but its tumor retention time still needs to be improved, which is an inherent shortcoming of small molecule inhibitors, and there are also differences in uptake in different types of tumors. Zboralsk et al. developed a FAP-2286 cyclic peptide compound with higher binding affinity and specificity, and retained the rapid renal clearance of small molecule inhibitors, but the tumor retention time still needs to be further extended. Therefore, it is still necessary to develop a new radioactive probe that can show high affinity and specificity for FAP, and has good tumor uptake and longer tumor retention time. Summary of the invention

[0005] The present invention first provides a compound BiFAPI or a pharmaceutically acceptable salt thereof that targets fibroblast activation protein. The compound BiFAPI has a structural formula shown in Formula I:

[0006]

[0007] The present invention further provides the use of the above-mentioned compound BiFAPI or a pharmaceutically acceptable salt thereof in the preparation of a radioactive probe targeting FAP.

[0008] The present invention also provides a radioactive probe targeting FAP, comprising the above-mentioned compound BiFAPI or a pharmaceutically acceptable salt thereof labeled with a radionuclide.

[0009] In certain embodiments, the radionuclide is selected from 68 Ga.

[0010] The present invention also provides a method for preparing the above-mentioned FAP-targeting radioactive probe, the method comprising the following steps:

[0011] 1) dissolving the above-mentioned compound BiFAPI in dimethyl sulfoxide to obtain a BiFAPI solution;

[0012] 2) Radionuclides are 68 Ga, adding sodium acetate solution to the BiFAPI solution to obtain a labeled precursor sodium acetate solution; then, 68 Ga]GaCl 3 The hydrochloric acid solution is added to the sodium acetate solution of the labeling precursor, mixed evenly, reacted at 90°C, and cooled to room temperature to obtain [ 68 Ga]Ga-BiFAPI.

[0013] In certain embodiments, the concentration of the BiFAPI solution is 1 mg / mL.

[0014] In some embodiments, the step further comprises obtaining 68 The step of determining the labeling rate by high performance liquid chromatography (radio-HPLC) with a radioactive detector is followed by the addition of Ga]Ga-BiFAPI.

[0015] In certain embodiments, the high performance liquid chromatography (radio-HPLC) with a radioactivity detector comprises:

[0016] The first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is an acetonitrile solution, and the gradient elution conditions are: 0 min, 100% of the first mobile phase; 0-10 min, 100%-0% of the first mobile phase; 10-15 min, 100% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

[0017] The present invention also provides a tumor imaging agent targeting FAP, comprising the above-mentioned compound BiFAPI or a pharmaceutically acceptable salt thereof, or the above-mentioned radioactive probe targeting FAP.

[0018] The present invention also provides the use of the above-mentioned compound BiFAPI or a pharmaceutically acceptable salt thereof, or the above-mentioned radioactive probe targeting FAP, or the above-mentioned imaging agent in the preparation of a tumor diagnostic preparation.

[0019] Compared with the prior art, the present invention has at least the following beneficial effects:

[0020] The present invention provides 68 The Ga]Ga-BiFAPI radioactive probe has the biological characteristics of specifically targeting FAP and can be used for early diagnosis, pathological research, disease progression and efficacy evaluation of tumors with high FAP expression. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 In Example 3 of the present invention, 68 Figure 3. Results of the cell uptake and inhibition experiments of Ga]Ga-BiFAPI.

[0022] Figure 2 In Example 3 of the present invention, 68 Ga]Ga-BiFAPI and [ 68 Comparison results of Ga]Ga-FAP-2286 cell uptake experiment.

[0023] Figure 3 This is a graph showing the results of determining the IC50 values ​​of BiFAPI and FAP-2286 in Example 4 of the present invention.

[0024] Figure 4 In Example 5 of the present invention, 68 Ga]Ga-BiFAPI or [ 68 Ga]Ga-FAP-2286 outflow experimental results.

[0025] Figure 5 In Example 6 of the present invention, 68 Ga]Ga-BiFAPI or [ 68 Figure 3. Results of internalization experiment of Ga]Ga-FAP-2286.

[0026] Figure 6 For the biodistribution experiment in Example 7 of the present invention [ 68 Distribution of Ga]Ga-BiFAPI in tumor-bearing mice.

[0027] Figure 7 For the biodistribution experiment in Example 7 of the present invention [ 68 Ga]Ga-BiFAPI and [ 68 Ga]Ga-FAP-2286 and [ 68 Ga]Ga-FAPI-04 and [ 68 In vivo distribution of Ga]Ga-BiFAPI in tumor-bearing mice in the blocking experiment.

[0028] Figure 8 For the biodistribution experiment in Example 7 of the present invention [ 68 Ga]Ga-BiFAPI and [ 68 Ga]Ga-FAP-2286 and [ 68 Ga]Ga-FAPI-04 and [ 68 Comparison of uptake of HT1080-FAP tumor and HT1080 tumor in Ga]Ga-BiFAPI blocking.

[0029] Fig. 9 HPLC spectrum of compound I.

[0030] Fig.10 MS spectrum of compound I. DETAILED DESCRIPTION

[0031] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0032] Terms and Definitions

[0033] CAFs, cancer-associated fibroblasts, tumor-associated fibroblasts;

[0034] ECM, extracellular matrix;

[0035] FAP, fibroblast activation protein, fibroblast activation protein;

[0036] DMSO, Dimethylsulfoxide;

[0037] PBS, phosphate buffer saline, phosphate buffered saline;

[0038] FAPI, fibroblast activation protein inhibitor, fibroblast activation protein inhibitor;

[0039] Example 1: Synthesis of radiolabeled ligand BIFAPI

[0040]

[0041] Synthesis reaction equation:

[0042]

[0043]

[0044] Synthesis method

[0045] Compound 1 (1 equivalent), compound 2 (1 equivalent), 1,3-dicyclohexylcarbodiimide (DCC, 1.2 equivalents), N-hydroxysuccinimide (HOSu, 1.2 equivalents) and N,N-diisopropylethylamine (DIPEA, 3 equivalents) were dissolved in dimethylformamide (DMF) and reacted at room temperature overnight. Piperidine was then added and reacted at room temperature for 2 hours, and compound 3 was obtained after purification by HPLC.

[0046] Compound 4 (1 equivalent), compound 5 (1 equivalent), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 1.2 equivalents), 1-hydroxybenzotriazole (HOBt, 1.2 equivalents) and N-methylmorpholine (NMM, 3 equivalents) were dissolved in dimethylformamide (DMF), reacted overnight at room temperature, ethyl acetate was added, washed with water and saturated brine, the organic phase was dried over anhydrous sodium sulfate, and the organic solvent was removed in vacuo to obtain an oily substance. Trifluoroacetic acid (TFA) was added to the oily substance, reacted at room temperature for 4 hours, and purified by HPLC to obtain compound 6.

[0047] Compound 3 (1 equivalent), compound 6 (1 equivalent), 1,3-dicyclohexylcarbodiimide (DCC, 1.2 equivalents), N-hydroxysuccinimide (HOSu, 1.2 equivalents) and N,N-diisopropylethylamine (DIPEA, 3 equivalents) were dissolved in dimethylformamide (DMF) and reacted at room temperature overnight. Piperidine was then added and reacted at room temperature for 2 hours, and compound 7 was obtained after purification by HPLC.

[0048] Compound 7 (1 equivalent), compound 8 (1 equivalent), 1,3-dicyclohexylcarbodiimide (DCC, 1.2 equivalents), N-hydroxysuccinimide (HOSu, 1.2 equivalents) and N,N-diisopropylethylamine (DIPEA, 3 equivalents) were dissolved in dimethylformamide (DMF) and reacted overnight at room temperature. Ethyl acetate was then added, washed with water and saturated brine, the organic phase was dried over anhydrous sodium sulfate, and the organic solvent was removed in vacuo to obtain an oil. Trifluoroacetic acid (TFA) was added to the oil, reacted at room temperature for 4 hours, and purified by HPLC to obtain compound I, the identification results of which are shown in Fig. 9 and Fig.10 . HRMS(ESI+)calcd forC101H141F2N20O26S3[M+2H]2+1092.48,found 1092.90.

[0049] Example 2 Radiolabeling of the ligand BiFAPI 68 Ga radiolabeling

[0050] (1) Dissolve 1 mg of the compound BiFAPI in DMSO to prepare a BiFAPI solution with a concentration of 1 μg / μL;

[0051] (2) Elute the germanium-gallium generator with 4 mL of high-purity 0.05 N hydrochloric acid solution, and discard the first 1.5 mL and the last 2 mL of the eluent;

[0052] (3) 0.5 mL of [ 6860 μL of 0.5N sodium acetate solution was added to the hydrochloric acid solution of Ga]GaCl3, at which the pH of the solution was about 4.0, and then 10 μL of BiFAPI solution prepared in step (1) was added thereto, mixed evenly, reacted at 90°C for 10 min, cooled to room temperature, and the labeling rate was determined by high performance liquid chromatography (radio-HPLC) with a radioactive detector to obtain [ 68 Ga]Ga-BiFAPI;

[0053] In the high performance liquid chromatography (radio-HPLC) with a radioactivity detector in step (3), the first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is an acetonitrile solution, and the gradient elution conditions are: 0 min, 100% of the first mobile phase; 0-10 min, 100%-0% of the first mobile phase; 10-15 min, 100% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

[0054] Example 3 Cellular uptake and inhibition experiments

[0055] (1) HT1080-FAP (FAP positive) cells (~1×10 5 / well) were inoculated in a 24-well plate and cultured in an incubator for 48 hours until the cell coverage was 90-100%. The culture medium was aspirated, the cells were washed twice with phosphate buffered saline, and 0.5 ml of 2 μCi / well of [ 68 Ga]Ga-BiFAPI or [ 68 Ga]Ga-FAP-2286 was incubated at 37°C for 10, 30, 60 and 120 min, and 100 μM / L FAP inhibitor UAMC1110 was used to block cellular uptake. After the incubation, the solution was aspirated and the cells were quickly washed three times with cold phosphate-buffered saline to terminate cellular uptake; all cells were lysed with sodium hydroxide and the lysate was collected for radioactivity counting.

[0056] (2) Figure 1 , 2 The results of in vitro cell uptake experiments show that: 68 The uptake of Ga]Ga-BiFAPI in HT1080-FAP (FAP-positive) cells in vitro was high, higher than that of [ 68 Ga]Ga-FAP-2286 uptake; after adding fibroblast activation protein inhibitor, [ 68 Ga]Ga-BiFAPI uptake was blocked, indicating that [ 68 Ga]Ga-BiFAPI specifically binds to fibroblast activation protein.

[0057] Example 4IC 50 Value determination

[0058] HT1080-FAP (FAP positive) cells (~1×10 5 / well) were inoculated in a 24-well plate and cultured in an incubator for 48 hours until the cell coverage was 90-100%. The culture medium was aspirated, the cells were washed twice with phosphate buffered saline, and 0.5 ml of 2 μCi / well of [ 68 Ga]Ga-BiFAPI and FAP-2286 and cold compound BiFAPI, so that the final concentrations of FAP-2286 and cold compound BiFAPI are 0.001, 0.01, 0.1, 1, 10, 100, 1000, 10000 nM, respectively. After incubation at 37°C for 60 minutes, the solution is aspirated, the cells are quickly washed three times with phosphate buffered saline to terminate cell uptake, all cells are lysed with sodium hydroxide, and the lysate is collected for radioactivity counting;

[0059] By IC 50 The experimental results of value determination show that: Figure 3 As shown in Figure 2, FAP-2286 and BiFAPI have high binding affinity to fibroblast activation protein, with IC 50 The values ​​were 6.58±1.60nM and 22.00±1.76nM, respectively, indicating that FAP-2286 and BiFAPI have similar affinities to the FAP receptor.

[0060] Example 5 Cell efflux experiment

[0061] (1) HT1080-FAP positive cells (~1×10 5 / well) were inoculated in a 24-well plate and cultured in an incubator for 48 hours until the cell coverage was 90-100%. The culture medium was aspirated, the cells were washed twice with phosphate buffered saline, and 0.5 ml of 2 μCi / well of [ 68 Ga]Ga-BiFAPI or [ 68 Ga]Ga-FAP-2286, incubate at 37°C for 30 minutes, aspirate the solution, quickly wash the cells twice with phosphate-buffered saline, add non-radioactive culture medium and incubate for 0, 10, 30, 60, and 120 minutes, remove the culture medium, quickly wash the cells three times with phosphate-buffered saline to terminate cell uptake; lyse all cells with sodium hydroxide, and collect the lysate for radioactivity counting.

[0062] Results: Figure 4 As shown, 68 The elution rate of Ga]Ga-BiFAPI within 2 h is less than [ 68 Ga]Ga-FAP-2286.

[0063] Example 6 Cell internalization experiment

[0064] HT1080-FAP positive cells (~1×10 5 / well) were inoculated in a 24-well plate and cultured in an incubator for 48 hours until the cell coverage was 90-100%. The culture medium was aspirated, the cells were washed twice with phosphate buffered saline, and 0.5 ml of 2 μCi / well of [ 68 Ga]Ga-BiFAPI or [ 68 Ga]Ga-FAP-2286, incubate at 37°C for 30 minutes, then aspirate the solution and quickly wash the cells twice with phosphate buffered saline. Add 0.5 mL of glycine-HCl solution to each well, collect the glycine-HCl solution into a tube after 5 minutes, wash the cells with PBS, and collect the PBS into the same tube. Repeat glycine-HCl and PBS once, and collect the solution. Lyse all cells with sodium hydroxide, and collect the lysate for radioactivity counting.

[0065] Results: Figure 5 As shown, 68 The internalization rate of Ga]Ga-BiFAPI within 2 h was faster than that of [ 68 Ga]Ga-FAP-2286.

[0066] Example 7 Biodistribution in tumor-bearing mice

[0067] 1. 68 Ga]Ga-BiFAPI,[ 68 Biodistribution of Ga]Ga-FAP-2286 in tumor-bearing mice

[0068] (1) Establishment of HT1080-FAP and HT1080 xenograft tumor nude mouse models: After 4-5 week-old BALB / C-nu / nu nude mice weighing 16-22 g were adaptively raised for one week, HT1080-FAP (FAP high expression) and HT1080 (FAP low expression) cells in the logarithmic phase were digested and centrifuged, and resuspended in PBS to make 5×10 7 The HT1080-FAP cell suspension was inoculated into the right axilla of nude mice, and the HT1080 cell suspension was inoculated into the left axilla of nude mice. Each nude mouse was inoculated with 100 μL of cell suspension on each side.

[0069] (2) Randomly divide 20 model mice into 5 groups, 4 mice in each group. 68 Ga]Ga-BiFAPI or [ 68After the Ga]Ga-FAP-2286 solution was diluted with physiological saline, each model mouse was injected with about 25μCi of the drug solution through the tail vein. After 10, 30, 60, and 120 minutes, the mouse was killed by cervical dislocation, and the tissues of interest were taken to measure the radioactivity count. Blocking experiment: excessive UAMC-1110 (2nmol / mouse) was added to [ 68 The mixture was mixed with Ga]Ga-BiFAPI solution (about 25 μCi) and injected through the tail vein. After 60 minutes, the mice were killed by cervical dislocation and the tissues of interest were obtained to measure the radioactivity count.

[0070] (3) From the results of biodistribution experiments, we can see that Figure 6 , 7 ,8,[ 68 Ga]Ga-BiFAPI had a high uptake in nude mouse HT1080-FAP tumors, but no significant uptake was observed in HT1080 tumors. 68 The uptake of Ga]Ga-BiFAPI reached the highest level at 30 min; the uptake of HT1080-FAP tumors in the blocking group was significantly reduced; the uptake of HT1080-FAP tumors on [ 68 The uptake of Ga]Ga-BiFAPI was higher than that of [ 68 Ga]Ga-FAP-2286.

[0071] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A compound BiFAPI targeting fibroblast activation protein or a pharmaceutically acceptable salt thereof, It is characterized in that The compound BiFAPI has the structural formula shown in Formula I:

2. Use of the compound BiFAPI or a pharmaceutically acceptable salt thereof as claimed in claim 1 in the preparation of a radioactive probe targeting FAP.

3. A radioactive probe targeting FAP, It is characterized in that The compound BiFAPI or a pharmaceutically acceptable salt thereof as claimed in claim 1 is labeled with a radionuclide.

4. The FAP-targeting radioactive probe according to claim 3, It is characterized in that The radionuclide is selected from 68 Ga.

5. A method for preparing a FAP-targeting radioactive probe as described in any one of claims 3 to 4, It is characterized in that The method comprises the following steps: 1) dissolving the compound BiFAPI according to claim 1 in dimethyl sulfoxide to obtain a BiFAPI solution; 2) Radionuclides are 68 Ga, adding sodium acetate solution to the BiFAPI solution to obtain a labeled precursor sodium acetate solution; then, 68 Ga]GaCl 3 The hydrochloric acid solution is added to the sodium acetate solution of the labeling precursor, mixed evenly, reacted at 90°C, and cooled to room temperature to obtain [ 68 Ga]Ga-BiFAPI.

6. The method for preparing the FAP-targeting radioactive probe according to claim 5, It is characterized in that The concentration of the BiFAPI solution is 1 mg / mL.

7. The preparation method according to any one of claims 5 to 6, It is characterized in that Also included in getting [ 68 The step of determining the labeling rate by high performance liquid chromatography (radio-HPLC) with a radioactive detector is followed by the addition of Ga]Ga-BiFAPI.

8. The preparation method according to claim 7, It is characterized in that The high performance liquid chromatography (radio-HPLC) with a radioactive detector includes: The first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is an acetonitrile solution, and the gradient elution conditions are: 0 min, 100% of the first mobile phase; 0-10 min, 100%-0% of the first mobile phase; 10-15 min, 100% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

9. A tumor imaging agent targeting FAP, It is characterized in that It comprises the compound BiFAPI or a pharmaceutically acceptable salt thereof as described in claim 1, or a radioactive probe targeting FAP as described in any one of claims 3-4.

10. Use of the compound BiFAPI or a pharmaceutically acceptable salt thereof as claimed in claim 1, or the radioactive probe targeting FAP as claimed in any one of claims 3 to 4, or the imaging agent as claimed in claim 9 in the preparation of a preparation for tumor diagnosis.